Pharmaniaga Berhad Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Pharmaniaga Berhad is gedaald met een gemiddeld jaarlijks percentage van -32.4%, terwijl de winst van de Healthcare -industrie jaarlijks groeide met 24.3%. De inkomsten zijn groeide met een gemiddeld percentage van 6% per jaar.

Belangrijke informatie

-32.4%

Groei van de winst

-32.0%

Groei van de winst per aandeel

Healthcare Groei van de industrie	31.5%
Inkomstengroei	6.0%
Rendement op eigen vermogen	n/a
Nettomarge	-1.6%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Jul 18

Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

May 09

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Apr 19

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Oct 03

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Jul 19

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Feb 18

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Dec 10

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Nov 24

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Aug 27

Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

May 28

Opbrengsten en kosten

Hoe Pharmaniaga Berhad geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

KLSE:PHARMA Opbrengsten, kosten en inkomsten (MYR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 24	3,479	-56	285
31 Mar 24	3,489	-57	297
31 Dec 23	3,404	-80	302
30 Sep 23	3,507	-667	377
30 Jun 23	3,487	-654	300
31 Mar 23	3,399	-655	295
31 Dec 22	3,481	-630	293
30 Sep 22	3,330	100	224
30 Jun 22	4,568	164	326
31 Mar 22	4,984	177	322
31 Dec 21	4,815	172	306
30 Sep 21	4,738	80	341
30 Jun 21	3,230	32	219
31 Mar 21	2,699	28	205
31 Dec 20	2,725	27	209
30 Sep 20	2,806	-145	223
30 Jun 20	2,898	-146	231
31 Mar 20	2,854	-146	229
31 Dec 19	2,821	-149	230
30 Sep 19	2,701	34	211
30 Jun 19	2,572	48	197
31 Mar 19	2,553	44	208
31 Dec 18	2,385	42	205
30 Sep 18	2,402	60	218
30 Jun 18	2,388	48	233
31 Mar 18	2,324	52	222
31 Dec 17	2,324	54	227
30 Sep 17	2,294	31	228
30 Jun 17	2,234	41	231
31 Mar 17	2,248	46	235
31 Dec 16	2,189	46	224
30 Sep 16	2,286	62	229
30 Jun 16	2,296	69	214
31 Mar 16	2,277	71	214
31 Dec 15	2,189	84	212
30 Sep 15	2,136	105	203
30 Jun 15	2,114	100	209
31 Mar 15	2,126	99	205
31 Dec 14	2,123	94	197
30 Sep 14	2,064	78	186
30 Jun 14	2,002	67	176
31 Mar 14	1,915	57	172
31 Dec 13	1,947	55	180

Kwaliteitswinsten: PHARMA is momenteel verliesgevend.

Groeiende winstmarge: PHARMA is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: PHARMA is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 32.4% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van PHARMA over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: PHARMA is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Healthcare industrie ( 1.6% ).

Rendement op eigen vermogen

Hoge ROE: De schulden van PHARMA zijn groter dan de activa, dus het is lastig om het rendement op het eigen vermogen te berekenen.

Pharmaniaga Berhad Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings released

First quarter 2024 earnings released: EPS: RM0.018 (vs RM0.002 in 1Q 2023)

Full year 2023 earnings released: RM0.057 loss per share (vs RM0.46 loss in FY 2022)

Third quarter 2023 earnings released: RM0.037 loss per share (vs RM0.007 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 2Q 2022)

First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.021 in 1Q 2022)

Recent updates

Pharmaniaga Berhad Announces Redesignation of Encik Zulkifli Bin Jafar from Executive Director to Managing Director, Effective September 1, 2024

Second quarter 2024 earnings released

High number of new directors

New minor risk - Share price stability

Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Now 20% overvalued after recent price rise

First quarter 2024 earnings released: EPS: RM0.018 (vs RM0.002 in 1Q 2023)

Now 24% undervalued after recent price drop

Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

Pharmaniaga Berhad, Annual General Meeting, Jun 05, 2024

High number of new directors

Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee

Pharmaniaga Berhad Announces the Retirement of Encik Mohamed Iqbal Abdul Rahman as Chief Operating Officer

New major risk - Revenue and earnings growth

Full year 2023 earnings released: RM0.057 loss per share (vs RM0.46 loss in FY 2022)

Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Director, Effective March 1, 2024

Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof, as Independent and Non Executive Director Effective March 1, 2024

Pharmaniaga Berhad Announces Resignation of Puan Dayana Rogayah Binti Omar as Non Independent and Non Executive Alternate Director

New minor risk - Share price stability

Third quarter 2023 earnings released: RM0.037 loss per share (vs RM0.007 profit in 3Q 2022)

Price target decreased by 19% to RM0.28

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 2Q 2022)

Pharmaniaga Berhad Announces Appointment of Encik Ahmad Shahredzuan Mohd Shariff as Non Independent and Non Executive Member of Risk Committee

New minor risk - Shareholder dilution

New minor risk - Market cap size

Pharmaniaga Berhad announced that it expects to receive MYR 44.20988 million in funding

Pharmaniaga Berhad Announces the Retirement of Dr Mary Jane Cardosa as Independent and Non Executive Member of Risk Committee

First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.021 in 1Q 2022)

Pharmaniaga Berhad Announces the Resignation of Datuk Dr Azhar Ahmad as Independent and Non Executive Director

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Full year 2022 earnings released: RM0.46 loss per share (vs RM0.13 profit in FY 2021)

Price target decreased by 33% to RM0.41

Pharmaniaga Berhad Announces Resignation of Najmil Faiz Mohamed Aris as Independent and Non Executive Member of Nomination and Remuneration Committee

Third quarter 2022 earnings released: EPS: RM0.007 (vs RM0.038 in 3Q 2021)

Pharmaniaga Berhad Declares Third Interim Dividend for the Third Quarter Ended 30 September 2022, payable on 22 February 2023

High number of new directors

Pharmaniaga Berhad (KLSE:PHARMA) entered into a Memorandum of Understanding to acquire JDMAS Commerce Sdn Bhd.

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Consensus EPS estimates fall by 13%

Price target decreased to RM0.75

Second quarter 2022 earnings released: EPS: RM0.001 (vs RM0.01 in 2Q 2021)

Pharmaniaga Berhad Announces Second Interim Dividend for the Year Ended December 31, 2022, Payable on October 04, 2022

Pharmaniaga Berhad Appoints Mary Jane Cardosa as Independent and Non Executive Member of Risk Committee

Pharmaniaga Berhad Appoints Mary Jane Cardosa as Independent and Non Executive Director

Pharmaniaga Berhad Appoints Datuk Lim Thean Shiang as Independent and Non Executive Director

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Price target decreased to RM0.87

Pharmaniaga Berhad Declares First Interim Dividend for the Financial Year Ending 31 December 2022, Payable on 06 July 2022

Pharmaniaga Berhad Appoints Abdul Razak Bin Ahmad as Independent and Non-Executive Member of Risk Committee

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Pharmaniaga Berhad, Annual General Meeting, Jun 13, 2022

High number of new and inexperienced directors

Upcoming dividend of RM0.05 per share

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Pharmaniaga Berhad Declares Fourth Interim Dividend for the Financial Year Ending 31 December 2021, Payable on 05 April 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Pharmaniaga Berhad Announces Re-Designation of Encik Zulkifli Jafar, Independent Director as Executive Director

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Consensus EPS estimates increase to RM0.09

Upcoming dividend of RM0.02 per share

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Third quarter 2021 earnings released: EPS RM0.038 (vs RM0.001 in 3Q 2020)

Upcoming dividend of RM0.015 per share

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Independent Non-Executive Director Zainal Shariff has left the company

Second quarter 2021 earnings released: EPS RM0.011 (vs RM0.008 in 2Q 2020)

Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

Investor sentiment improved over the past week